The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
The post and conversation are about the long-term side effects of using Dutasteride and Finasteride for hair loss, including issues like raised liver enzymes, high cholesterol, and loss of libido. The user advises regular blood work and careful monitoring for those using these treatments.
The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
A user tried to advise someone on hair loss treatments like Minoxidil, finasteride, and RU58841, but the person didn't listen. Others supported the effort but noted it's up to the individual to take the advice.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
The user is experiencing low libido and mood swings after starting a low dose of topical finasteride. They are considering further blood tests to investigate low testosterone levels and other hormonal factors.
The conversation is about the potential effectiveness of a hair loss treatment called pyrilutamide. One person has been using it since September and reports positive results.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.
The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.
The user plans to use RU58841 in the morning and Pyrilutamide in the evening for hair loss treatment, considering replacing Fluridil with Pyrilutamide. They believe Pyrilutamide is effective.
The user shares their experience with hair loss treatments, specifically finasteride, and discusses the side effects like lowered libido and motivation. They recommend trying tyrosine to counter these effects, noting it improved their libido and energy levels.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.
The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.
The user has been using 1.25 mg of oral minoxidil and finasteride since September 2025 to address diffuse hair thinning, and is considering trying a new shampoo. Other users suggest increasing the minoxidil dose and trying dutasteride.
RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.
RU58841 may still be potent after being left unopened for four months if protected from light and air. A user reported hair improvement using RU58841 with minoxidil, without major shedding, over 2.5 years.
A user received a prescription for Dutasteride 0.5 in Europe and asked about the brand. Replies confirmed the brand's quality and suggested using the cheapest gelatin capsule form.
RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
The conversation is about finding ethanol in California for mixing with RU58841 for hair loss treatment. Users suggest alternatives like high-proof alcohol from liquor stores or purchasing lab-grade ethanol online.
The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.